# Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia

> **NCT02739984** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 424 (actual)

## Conditions studied

- Hypercholesterolemia
- Mixed Dyslipidemia
- Type 2 Diabetes

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Placebo to Evolocumab

## Key facts

- **NCT ID:** NCT02739984
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-17
- **Primary completion:** 2017-08-03
- **Final completion:** 2017-08-03
- **Target enrollment:** 424 (ACTUAL)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739984, "Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02739984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*